Role of Kampo medicine in integrative cancer therapy

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Yamakawa, Jun Ichi ^a   Motoo, Yoshiharu ^a   Moriya, Junji ^a   Ogawa, Masao ^a   Uenishi, Hiroaki ^a   Akazawa, Sumiyo ^a   Sasagawa, Toshiyuki ^a   Nishio, Matomo ^a   Kobayashi, Junji ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; JUZENTAIHOTO EXTRACT; KAMPO; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CANCER THERAPY; CLINICAL FEATURE; HUMAN; JAPAN; PALLIATIVE THERAPY; PATIENT CARE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW;

EID: 84880855814     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/570848     Document Type: Review

References (55)

1. Chua T. C., Saxena A., Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: a review of current results. Surgical Oncology 2011 20 4 e161 e168 2-s2.0-80053644199 10.1016/j.suronc.2011. 05.003
2. Waddell T., Cunningham D., Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours. British Journal of Surgery 2013 100 5 14
3. Ferrara F., Schiffer C. A., Acute myeloid leukaemia in adults. The Lancet 2013 381 484 495
4. Pennathur A., Gibson M. K., Jobe B. A., Oesophageal carcinoma. The Lancet 2013 381 400 412
5. Liu J. J., Lu J., McKeage M. J., Membrane transporters as determinants of the pharmacology of platinum anticancer drugs. Current Cancer Drug Targets 2012 12 962 986
6. MacEdo L. T., Ribeiro J., Curigliano G., Fumagalli L., Locatelli M., Carvalheira J. B. C., Quintela A., Bertelli S., De Cobelli O., Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma. European Journal of Surgical Oncology 2011 37 7 558 562 2-s2.0-79959566837 10.1016/j.ejso.2011.04.005
7. Song X., Long S. R., Barber B., Kassed C. A., Healey M., Jones C., Zhao Z., Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer. Current Clinical Pharmacology 2012 7 1 56 65 2-s2.0-84857125097 10.2174/157488412799218806
8. Deenen M. J., Cats A., Beijnen J. H., Schellens J. H. M., Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist 2011 16 6 820 834 2-s2.0-79959614317 10.1634/ theoncologist.2010-0259
9. Hsu E. S., A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. American Journal of Therapeutics 2010 17 5 476 486 2-s2.0-77957784497 10.1097/MJT.0b013e3181ea7821
10. Lee C., Gianos M., Klaustermeyer W. B., Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Annals of Allergy, Asthma and Immunology 2009 102 3 179 187 2-s2.0-63449112670
11. Bardy J., Slevin N. J., Mais K. L., Molassiotis A., A systematic review of honey uses and its potential value within oncology care. Journal of Clinical Nursing 2008 17 19 2604 2623 2-s2.0-52049114694 10.1111/j.1365-2702.2008.02304.x
12. Grande C., Villanueva M. J., Huidobro G., Casal J., Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clinical and Translational Oncology 2007 9 9 578 581 2-s2.0-38449109340 10.1007/s12094-007-0106-4
13. Rodriguez-Frias E. A., Lee W. M., Cancer chemotherapy II: atypical hepatic injuries. Clinics in Liver Disease 2007 11 3 663 676 2-s2.0-34548113537 10.1016/j.cld.2007.06.012 (Pubitemid 47302348)
14. Rodriguez-Frias E. A., Lee W. M., Cancer chemotherapy I: hepatocellular injury. Clinics in Liver Disease 2007 11 3 641 662 2-s2.0-34548116583 10.1016/j.cld.2007.06.007 (Pubitemid 47302346)
15. Bosch T. M., Meijerman I., Beijnen J. H., Schellens J. H. M., Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clinical Pharmacokinetics 2006 45 3 253 285 2-s2.0-33644647219 10.2165/00003088-200645030-00003 (Pubitemid 43327492)
16. Ando M., Hasegawa Y., Ando Y., Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Investigational New Drugs 2005 23 6 539 545 2-s2.0-29744447165 10.1007/s10637-005-4022-6 (Pubitemid 43162473)
17. Ando Y., Hasegawa Y., Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metabolism Reviews 2005 37 3 565 574 2-s2.0-26444594410 10.1080/03602530500316254 (Pubitemid 41434162)
18. Bensadoun R.-J., Magné N., Marcy P.-Y., Demard F., Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. European Archives of Oto-Rhino-Laryngology 2001 258 9 481 487 2-s2.0-0035211403 10.1007/s004050100368 (Pubitemid 33141265)
19. Nahin R. L., Use of the best case series to evaluate complementary and alternative therapies for cancer: a systematic review. Seminars in Oncology 2002 29 6 552 562 2-s2.0-0036970437 10.1053/sonc.2002.50004 (Pubitemid 36134978)
20. White J. D., Complementary and alternative medicine research: a National Cancer Institute perspective. Seminars in Oncology 2002 29 6 546 551 2-s2.0-0036972112 10.1053/sonc.2002.50003 (Pubitemid 36134977)
21. Richardson M. A., Straus S. E., Complementary and alternative medicine: opportunities and challenges for cancer management and research. Seminars in Oncology 2002 29 6 531 545 2-s2.0-0036968184 10.1053/sonc.2002.50002 (Pubitemid 36134976)
22. Terasawa K., Evidence-based reconstruction of Kampo medicine: part I-is Kampo CAM? Evidence-Based Complementary and Alternative Medicine 2004 1 11 16
23. Terasawa K., Evidence-based reconstruction of Kampo medicine: part II-the Concept of Sho. Evidence-Based Complementary and Alternative Medicine 2004 1 119 123
24. Terasawa K., Evidence-based reconstruction of Kampo medicine: part-III-How Should Kampo be Evaluated? Evidence-Based Complementary and Alternative Medicine 2004 1 219 222
25. Motoo Y., Seki T., Tsutani K., Traditional Japanese medicine, Kampo: its history and current status. Chinese Journal of Integrative Medicine 2011 17 2 85 87 2-s2.0-79952550846 10.1007/s11655-011-0653-y
26. White J. D., The National Cancer Institute's perspective and agenda for promoting awareness and research on alternative therapies for cancer. Journal of Alternative and Complementary Medicine 2002 8 5 545 550 2-s2.0-0036805458 (Pubitemid 35291588)
27. Walker L. A., Budd S., UK: the current state of regulation of complementary and alternative medicine. Complementary Therapies in Medicine 2002 10 1 8 13 2-s2.0-0036056586 10.1054/ctim.2002.0522
28. White J. D., Cancer: current research in alternative therapies. Primary Care 2002 29 379 392 (Pubitemid 34760380)
29. Markman M., Safety issues in using complementary and alternative medicine. Journal of Clinical Oncology 2002 20 18, supplement 39S 41S 2-s2.0-0037106272
30. Yamakawa J.-I., Ishigaki Y., Takano F., Takahashi T., Yoshida J., Moriya J., Takata T., Tatsuno T., Sasaki K., Ohta T., Takegami T., Yoshizaki F., The Kampo medicines orengedokuto, bofutsushosan and boiogito have different activities to regulate gene expressions in differentiated rat white adipocytes: comprehensive analysis of genetic profiles. Biological and Pharmaceutical Bulletin 2008 31 11 2083 2089 2-s2.0-55549141875 10.1248/bpb.31.2083
31. Yamakawa J.-I., Moriya J., Takahashi T., Ishige A., Motoo Y., Yoshizaki F., Kanda T., A Kampo medicine, boiogito, inhibits obesity in ovariectomized rats. Evidence-Based Complementary and Alternative Medicine 2010 7 1 87 95 2-s2.0-77249150919 10.1093/ecam/nem153
32. Gao J. J., Song P. P., Qi F. H., Evidence-based research on traditional Japanese medicine, Kampo, in treatment of gastrointestinal cancer in Japan. Drug Discoveries & Therapeutics 2012 6 1 8
33. Yoshiro H., Sekiya N., Chino A., Three cases of chemotherapy-induced peripheral neuropathy successfully treated with therapy based on kampo diagnosis. Alternative Therapies in Health & Medicine 2011 17 26 30
34. Yasunaga H., Miyata H., Horiguchi H., Kuwabara K., Hashimoto H., Matsuda S., Effect of the Japanese herbal kampo medicine Dai-kenchu-to on postoperative adhesive small bowel obstruction requiring long-tube decompression: a propensity score analysis. Evidence-Based Complementary and Alternative Medicine 2011 2011 7 2-s2.0-79959241171 10.1155/2011/264289 264289
35. Sharma R., Tobin P., Clarke S. J., Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. The Lancet Oncology 2005 6 2 93 102 2-s2.0-13344294983 10.1016/S1470-2045(05)01735-3 (Pubitemid 40197703)
36. Mori K., Kondo T., Kamiyama Y., Kano Y., Tominaga K., Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 2003 51 5 403 406 2-s2.0-0038356729 (Pubitemid 36649137)
37. Takeda T., Yamaguchi T., Yaegashi N., Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines. International Journal of Clinical Oncology 2012 17 2 143 149 2-s2.0-79959416220 10.1007/s10147-011-0271-x
38. Iwase S., Yamaguchi T., Miyaji T., The clinical use of Kampo medicines (traditional Japanese herbal treatments) for controlling cancer patients' symptoms in Japan: a national cross-sectional survey. BMC Complementary and Alternative Medicine 2012 20 222
39. Ito A., Munakata K., Imazu Y., First nationwide attitude survey of Japanese physicians on the use of traditional Japanese medicine (Kampo) in cancer treatment. Evidence-Based Complementary and Alternative Medicine 2012 2012 8 957082 10.1155/2012/957082
40. Tsutsui T., Muramatsu N., Japan's universal long-term care system reform of 2005: containing costs and realizing a vision. Journal of the American Geriatrics Society 2007 55 9 1458 1463 2-s2.0-34548229340 10.1111/j.1532-5415. 2007.01281.x (Pubitemid 47329225)
41. Ikegami N., The economics of health care in Japan. Science 1992 258 614 618 (Pubitemid 23366289)
42. Kamiyama H., Takano S., Ishikawa E., Tsuboi K., Matsumura A., Anti-angiogenic and immunomodulatory effect of the herbal medicine "Juzen-taiho-to" on malignant glioma. Biological and Pharmaceutical Bulletin 2005 28 11 2111 2116 2-s2.0-27744567135 10.1248/bpb.28.2111 (Pubitemid 41634261)
43. Tagami K., Niwa K., Lian Z., Gao J., Mori H., Tamaya T., Preventive effect of Juzen-taiho-to on endometrial carcinogenesis in mice is based on Shimotsu-to constituent. Biological and Pharmaceutical Bulletin 2004 27 2 156 161 2-s2.0-16544389311 10.1248/bpb.27.156 (Pubitemid 41694689)
44. Mori H., Niwa K., Zheng Q., Yamada Y., Sakata K., Yoshimi N., Cell proliferation in cancer prevention; effects of preventive agents on estrogen-related endometrial carcinogenesis model and on an in vitro model in human colorectal cells. Mutation Research 2001 480-481 201 207 2-s2.0-0035451496 (Pubitemid 32744828)
45. Matsuo M., Tani T., Saiki I., Organ selectivity of Juzen-taiho-to and Ninjin-yoei-to in the expression of anti-metastatic efficacy. Journal of Traditional Medicines 2002 19 93 97
46. Onishi Y., Yamaura T., Tauchi K., Sakamoto T., Tsukada K., Nunome S., Komatsu Y., Saiki I., Expression of the anti-metastatic effect induced by Juzen-taiho-to is based on the content of Shimotsu-to constituents. Biological and Pharmaceutical Bulletin 1998 21 7 761 765 2-s2.0-0031858468 (Pubitemid 28374454)
47. Saiki I., A Kampo medicine "Juzen-taiho-to"-prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biological and Pharmaceutical Bulletin 2000 23 6 677 688 2-s2.0-0033943563 (Pubitemid 30435069)
48. Ishikawa S., Ishikawa T., Asano K., Fujiwara H., Okada M., Sunagawa M., Hisamitsu T., Suppressive effect of Juzentaihoto on vascularization induced by B16 melanoma cells in vitro and in vivo. Evidence-Based Complementary and Alternative Medicine 2012 2012 9 2-s2.0-84855170467 10.1155/2012/945714 945714
49. Utsuyama M., Seidlar H., Kitagawa M., Hirokawa K., Immunological restoration and anti-tumor effect by Japanese herbal medicine in aged mice. Mechanisms of Ageing and Development 2001 122 3 341 352 2-s2.0-0035047022 10.1016/S0047-6374(00)00249-9 (Pubitemid 32322449)
50. Muraishi Y., Mitani N., Yamaura T., Fuse H., Saiki I., Effect of interferon- α A/D in combination with the Japanese and Chinese traditional herbal medicine Juzen-taiho-to on lung metastasis of murine renal cell carcinoma. Anticancer Research 2000 20 5 2931 2937 2-s2.0-0033786114
51. Ikemoto T., Shimada M., Iwahashi S., Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. 2013 10.1007/s10147-013-0529-6
52. Munakata K., Takashima K., Nishiyama M., Asano N., Mase A., Hioki K., Ohnishi Y., Yamamoto M., Watanabe K., Microarray analysis on germfree mice elucidates the primary target of a traditional Japanese medicine juzentaihoto: acceleration of IFN- α response via affecting the ISGF3-IRF7 signaling cascade. BMC Genomics 2012 13 1, article 30 2-s2.0-84855869716 10.1186/1471-2164-13-30
53. Ogawa K., Omatsu T., Matsumoto C., Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect. BMC Complementary and Alternative Medicine 2012 9 article 118
54. Takegawa Y., Ikushima H., Ozaki K., Furutani S., Kawanaka T., Kudoh T., Harada M., Can Kampo therapy prolong the life of cancer patients? Journal of Medical Investigation 2008 55 1-2 99 105 2-s2.0-43149121073 10.2152/jmi.55.99 (Pubitemid 351643599)
55. Satou H., Arakawa S., Inhibitory effect of Kampo (japanese traditional herbal medicine) therapy on the development of hepatocellular carcinoma in patients with HCV-related chronic hepatic disease: usefulness of Kampo therapy based on traditional theory. Kampo Medicine 2004 55 455 461